CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 13 pages
Gregg C. Sylvester, MD, MPH ACIP Meeting Pregnancy Outcomes with ccIIV4 (Flucelvax); Post Marketing Study October 25, 2023 2Study Overview Purpose Post -marketing commitment Main Objective Evaluate specific pregnancy and fetus/infant outcomes Study Design Prospective, observational safety study Study Population Patients immunized with ccIIV4 as part of routine obstetrical care Scientific Oversight CommitteeTeratologist, blinded to exposure timing, reviewed and classified reported…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 37 pages
Safety of Simultaneous versus Sequential Administration of mRNA COVID -19 and Quadrivalent Inactivated Influenza (IIV4) Vaccines: A Randomized Placebo Controlled Trial (ClinicalTrials.gov ID: NCT05028361) Emmanuel “Chip” Walter MD, MPH ACIP October 25, 2023 Disclaimer •The findings and conclusions in this presentation are those of the presenter and do not necessarily represent the official position of the Centers for Disease Control and Prevention •Mention of a product or company name is…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 31 pages
Kenneth Schmader, MD ACIP Meeting October 25, 2023 Safety of Simultaneous Vaccination with Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (allV4) (ClinicalTrials.gov ID: NCT05007041) Disclaimer •The findings and conclusions in this presentation are those of the presenter and do not necessarily represent the official position of the Centers for Disease Control and Prevention •Mention of a product or company name is for identification purposes only…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 20 pages
National Center for Emerging and Zoonotic Infectious Diseases Update on COVID -19 and influenza vaccine safety Advisory Committee on Immunization Practices (ACIP) meeting October 25, 2023 Tom T. Shimabukuro, MD, MPH, MBA Director, Immunization Safety Office Division of Healthcare Quality Promotion Centers for Disease Control and Prevention (CDC) Key points up front 2▪A statistical signal for ischemic stroke after Pfizer -BioNTech bivalent mRNA COVID -19 vaccine was detected in CDC’s Vaccine…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 11 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 61 pages
! "#$%#& ' $ ()* + $ , !"- . ! / 0 $"#!1!"! / 0 2 3 34%$5$36"$3 2 #! , 7 4 . /2 %!#1-55 2 %- . 2 $%#!" 2 !# 80-9 !9"$46-% , %4 3 8 !"$ : 6"!1 2 $4#;7<=> ? @A, $#!# B C DEFGE HIJ…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 50 pages
! " #$ % & ' % ()* ! " #$ % & + , - . / 0 1 2 34 5 6 78 9 :4;<< 5 = ; > 3 ? 5 8 ? 3 @ 5 = 3 ? ;8 A ;4 5=B23<3…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
CHIKUNGUNYA VACCINES Beth Bell, MD, MPH Chair, ACIP Chikungunya Vaccines Work GroupACIP Meeting October 26, 2023 Background Expected licensure date for Valneva’s chikungunya vaccine revised from August 2023 to November 2023 No chikungunya vaccine ever licensed in United States or globally No existing ACIP chikungunya vaccine recommendations Chikungunya Vaccines Work Group is developing policy options for ACIP’s consideration for use of chikungunya vaccine among U.S. persons at risk of …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 67 pages
National Center for Emerging and Zoonotic Infectious Diseases EVIDENCE TO RECOMMENDATIONS FOR CHIKUNGUNYA VACCINE USE AMONG ADULT TRAVELERS Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, October 26, 2023 Chikungunya virus and transmission Alphavirus Primarily transmitted by Aedes aegypti and Aedes albopictus Uncommon modes of transmission –Laboratory exposure…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 15 pages
National Center for Emerging and Zoonotic Infectious Diseases EVIDENCE TO RECOMMENDATIONS FOR CHIKUNGUNYA VACCINE USE AMONG LABORATORY WORKERS Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, October 26, 2023 Infections among laboratory workers At least 44 chikungunya virus infections identified among laboratory workers worldwide over ~ 50 years1–3 –43 cases overt disease, 1…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 11 pages
Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Updates on Dengue Vaccines Wilbur Chen, MD October 26, 2023 Dengue is endemic in 6U.S. territories and freely associated states. Dengvaxia ™ACIP Recommendation June 2021 Three doses of Dengvaxia are indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4 in people 9–16 years old with: •laboratory confirmation of previous dengue virus infection AND…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. ACIP COVID -19 Vaccines Work Group Dr. Matthew F. Daley, Work Group Chair October 26, 2023 ▪September 11, 2023 –FDA authorized the updated mRNA COVID -19 vaccines for use…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Implementation Update on 2023 –2024 COVID -19 Vaccines Shannon Stokley, DrPH Immunization Services Division Centers for Disease Control and Prevention Commercialization…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 21 pages
cdc.gov/coronavirus Summary and Work Group Considerations Megan Wallace, DrPH, MPH ACIP Meeting June 23 , 2023 U.S. COVID -19 vaccine uptake among ages ≥12 years, August 2021 -June 2023 01,000,0002,000,0003,000,0004,000,0005,000,0006,000,0007,000,000 Primary Series, Adolescents Ages 12-17 Primary Series, Adults Ages 18-49 Primary Series, Adults Ages 50-64 Primary Series, Adults Ages 65+ Booster, Adolescents Ages 12-17 Booster, Adults Ages 18-49 Booster, Adults Ages 50-64 Booster, Adults Ages…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 8 pages
cdc.gov/coronavirus ACIP COVID -19 Vaccines Work Group Dr. Matthew F. Daley, Work Group Chair April 19, 2023 ▪April 18, 2023: FDA1updated COVID -19 vaccine emergency use authorizations (EUAs): –Use of bivalent mRNA vaccines for all doses/indications administered to individuals ages 6 months and older –Additional dose(s) for certain populationsCOVID -19 vaccine update: FDA authorizations 21. https://www.fda.gov/news -events/press -announcements/coronavirus -covid -19-update -fda-authorizes…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 13 pages
For more information: www.cdc.gov/COVID19 COVID -19 Vaccine Program Updates Georgina Peacock, MD, MPH, FAAP Director, Immunization Services Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention (CDC) Overarching Objectives for the U.S. COVID -19 Vaccination Program Ensure safety and effectiveness of COVID -19 vaccinesReduce mortality, morbidity, and incidence of COVID -19 diseaseHelp minimize disruption to society and economy,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 29 pages
National Center for Emerging and Zoonotic Infectious Diseases mRNA COVID -19 bivalent booster vaccine safety update Advisory Committee on Immunization Practices (ACIP) meeting April 19, 2023 Tom T. Shimabukuro, MD, MPH, MBA Director, Immunization Safety Office Division of Healthcare Quality Promotion Centers for Disease Control and Prevention (CDC) Topics ▪Describe current data on ischemic stroke following mRNA COVID -19 bivalent booster vaccination •CDC’s Vaccine Safety Datalink (VSD)…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 11 pages
National Center for Emerging and Zoonotic Infectious Diseases Update: v -safe after vaccination health checker Advisory Committee on Immunization Practices (ACIP) meeting April 19, 2023 Tom T. Shimabukuro, MD, MPH, MBA Director, Immunization Safety Office Division of Healthcare Quality Promotion Centers for Disease Control and Prevention (CDC) Topics ▪Overview of v -safe ▪Contributions of v -safe to the COVID -19 response ▪Historical and current participation in v -safe ▪Planning for the…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 25 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases COVID-19 vaccine effectiveness updates 19 April 2023 Ruth Link-Gelles, PhD, MPH LCDR, US…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 41 pages
cdc.gov/coronavirus Updates to COVID -19 vaccine policy : Considerations for Future Planning Sara Oliver, MD, MSPH ACIP Meeting April 19, 2023 U.S. COVID -19 vaccine uptake among ages ≥12 years, August 2021 -January 2023 Source: IZ Data Lake 01,000,0002,000,0003,000,0004,000,0005,000,0006,000,0007,000,000 Primary Series, Ages 12-17 Primary Series, Adults Ages 18-49 Primary Series, Adults Ages 50-64 Primary Series, Adults Ages 65+ Booster, Ages 12-17 Booster, Adults Ages 18-49 Booster,…